Trace of chestnut on platelets proliferation in male rats: In vivo study

The study seeks the efficacy of the chestnut extract on platelet proliferation and its function in guaranteeing more tangible physiological information about unexpected mortality caused by thrombus formation. Twenty-eight male adult rats were organized into two sets, each with 14 rats, at two intervals (14 and 35 days): the untreated set and the set that received chestnuts (600 mg/kg body weight) orally. Fourteen days after treatment, fourteen rats perished. The remaining half of the animals were left and then allocated into two sets in the untreated and treated groups with chestnuts at the same dose for 35 days. Findings demonstrate a significant reduction in thrombopoietin following 14 days of chestnut administration, as well as platelet counts at 14 and 35 days comparable to untreated rats, while hikes up hormone level and P-LCR at the 35th day of treatment; however, clotting time at both intervals prolonged about untreated rats. Between two intervals, chestnuts increased thrombopoietin levels, clotting time, and platelet count at 35 days, compared to the same group at 14 days of treatment. Immunohistochemistry at 14 and 35 days revealed that IL-3 was expressed strongly in the untreated rats' bones but only moderately in the chestnut group. Furthermore, at two intervals, rat's sans treatment exhibits robust VEGF expression in their aorta, whereas rats with chestnut extract dosages showcase weak expression. As a recap, chestnut hinders platelet proliferation by interfering with thrombopoietin, thrombocyte numbers, and IL-3 and acting as an anti-angiogenetic and anti-thrombogenic substance.